Heat Biologics

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

Investments expected to accelerate development timelines and reduce development expenses Investments expected to accelerate development timelines and reduce development expenses

Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters

The stock price of Heat Biologics Inc (NASDAQ: HTBX) increased by 40.15%. This is why it happened.

HTBX Stock Price: 40.15% Increase Explanation

Heat Biologics Inc. (NASDAQ:HTBX) shares traded higher Thursday after the company filed for a patent titled “GP96-Based Cancer Therapy.” The stock was trending on StockTwits throughout the day and is likely also moving as retail traders push the stock higher.

Heat Biologics Surges On Patent Filing

Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting

Heat Biologics Inc (NASDAQ: HTBX) has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC) patients. The data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study

DURHAM, N.C., May 20, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company's lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. The ASCO Annual Meeting is the largest international conference to showcase the latest advancements in oncology.

Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that PTX-35 will be featured in several presentations and panel discussions at the 3rd Annual Treg Directed Therapies Summit on May 19-20. PTX-35 is a novel, potential first-in-class antibody modulating TNFRSF25 (death receptor 3 or DR3), a receptor that is preferentially expressed by antigen-experienced T-cells.

Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit

DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) --  Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics' product portfolio.

Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the first quarter ended March 31, 2021.

Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021. PTX-35 is the company's first antibody-based product, currently in a Phase 1 clinical trial for the treatment of patients with solid tumors.

Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020. Jeff Wolf, Chief Executive Officer of Heat, commented, "We made tremendous progress on our clinical programs in 2020.

Heat Biologics Provides Year-End Business Update

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference , hosted by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference (link) on March 17th - 19th and will be posted on Heat Biologics' website (link) after March 19th.

Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Heat Biologics (HTBX) stock is heating up on Wednesday following new coverage from Cantor Fitzgerald analyst Kristen Kluska. The post HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today appeared first on InvestorPlace.

HTBX Stock: Why Shares of Heat Biologics Are Blazing Higher Today

The stock price of Heat Biologics, Inc. (Nasdaq: HTBX) has increased by over 25% pre-market. This is why it happened.

HTBX Stock Price Increases Over 25% Pre-Market: Why It Happened

Heat Biologics said Tuesday adding its experimental drug to Bristol Myers Squibb's Opdivo helped more lung-cancer patients survive. In response, HTBX stock catapulted.

Heat Biologics Catapults After Drug Regimen Boosts Lung-Cancer Survival

The stock price of Heat Biologics Inc (NASDAQ:HTBX) increased by over 103.1% in its day high. This is why it happened.

HTBX Stock Price Increased 103.1% In Day High: Why It Happened

Heat Biologics (HTBX) stock is heating up on Tuesday after revealing interim data from a Phase 2 trial of its lung cancer treatment. The post Heat Biologics News: Why HTBX Stock Is Going Gangbusters Today appeared first on InvestorPlace.

Heat Biologics News: Why HTBX Stock Is Going Gangbusters Today

Shares of Heat Biologics Inc. more than doubled in very active trading Tuesday, after the biopharmaceutical company focused on modulating the immune system reported "positive" interim data from a Phase 2 trial of its lung cancer treatment. The stock soared 115% toward a seven-month high ahead of the open on volume of 15.1 million shares, which compares with the full-day average of 1.4 million shares over the past 30 days.

Heat Biologics stock more than doubles after 'positive' trial data of its lung cancer treatment

Heat Biologics Inc (NASDAQ: HTBX) soars in premarket on the heels of encouraging interim data from the Phase 2 trial evaluating HS-110, in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC). Median progression-free survival (PFS) of 1.8 months and median overall survival (OS) of 24.6 months was observed in checkpoint inhibitor naïve patients with advanced NSCLC (cohort A, N = 47).

Heat Biologics Cell Therapy Shows Survival Benefit In Mid-Stage Lung Cancer Study, Shares Rally

The stock price of Heat Biologics Inc (NASDAQ: HTBX) has increased by over 6%. This is why it happened.

HTBX Stock Price Increases Over 6% Pre-Market: Why It Happened

Heat Biologics: Investors Would Be Wise To Hold Off Until 2H 2021 Clinical Trial Interim Results

DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has transferred its gp96-based COVID-19 vaccine cell line ("ZVX-60") to Waisman Biomanufacturing to initiate the manufacturing process for ZVX-60, which is being developed for use as either a standalone vaccine, or in combination with other vaccines, to enhance prophylactic protection against COVID-19. Jeff Wolf, Heat's CEO, commented, "Initiation of our manufacturing process is an important milestone as we progress ZVX-60 into human clinical trials.

Heat Biologics Commences Manufacturing Process for ZVX-60

DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announces it has appointed William Ostrander as its Chief Financial Officer, effective January 4, 2021. Mr. Ostrander has over two decades of experience in financial management at public and private companies and previously served as the Company's Vice President of Finance since joining in September 2019.

Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Esperion Therapeutics

Bioline RX

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI. Esprit Holdings is an international fashion brand whose operations include Retail, Wholesale and Licensing.

News for Heat Biologics Stock (HTBX)